Role of Ginkgo Biloba Extract in IUGR

NCT02425436 | Completed Phase 2

• 1 other identifier: Tibonina/ IUGR
• Study Type: interventional
• Target: 226
• Locations: 0 countries
• Sites: N/A

Brief Summary

The use of herbal medicinal products is increasing enormously in recent years, mainly among women, who use them for the most varied purposes, such as in menstrual problems, menopausal symptoms, mood disturbances and to strengthen their bones. Most of these benefits are due to the flavonoids present in these products. These flavonoids have anticarcinogenic, antiviral, antioxidant and antiinflammatory activities, as well as being used in the treatment of osteoporosis, menopausal symptoms and cardiovascular diseases . Besides the benefits from the consumption of flavonoids, little is known about their safety and potentially harmful toxic effects, such as mutagenicity and genotoxicity which might occur if taken in large doses . Safety of Ginkgo biloba during pregnancy or lactation was not criticized in literature. Roasted and raw ginkgo seed were not reported in the evidence-based medicine literature as being either safe or contraindicated in pregnancy or lactation. A higher incidence of postpartum hemorrhage was reported in the literature when associated with a 3-month ingestion of Ginkgo Biloba extract. Flavonoids are components of Ginkgo biloba L. (Ginkgoaceae), a medicinal plant widely used by the population . G. biloba has its origin in China, Korea and Japan where its fruits and leaves have been used as food and medicine for a long time. The extract of G. biloba (EGb) is composed of different terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones and alkylphenols . The major flavonoids in the extract are kaempferol, quercetin and isorhamnetin\] whose metabolites were found in the blood of rats and in human urine after oral administration of EGb. Due to its actions as an anti-inflammatory and antioxidant, EGb has been largely used in the treatment of Alzheimer's disease, pre-menstrual syndrome, cerebrovascular insufficiency and peripheral arterial occlusive disease . In folk medicine, EGb is used as a vermifuge, to induce labor, for the treatment of bronchitis, chronic rhinitis, chilblains, arthritis and edema . The aim of this study was to evaluate the effect of oral supplementation of Ginkgo Biloba extract on the fetal weight as well as feto-maternal blood flow in cases of intrauterine growth restriction.

Conditions

Intrauterine Growth Restriction (IUGR)

Outcome Measures

Primary Outcomes (1)

• Fetal weight (gm)

  one and half year

Secondary Outcomes (3)

• Doppler blood flow changes in uterine arteries indices

  one and half year

• Doppler blood flow changes in umbilical arteries indices

  one and half year

• Doppler blood flow changes in middle cerebral artery indices

  one and half year

Study Arms (2)

Ginkgo Biloba Extract group

ACTIVE COMPARATOR

This group received Ginko Biloba, two tablets per day

Drug: Ginkgo Biloba Extract

Placebo group

PLACEBO COMPARATOR

This group received placebo two tablets per day .

Other: Placebo

Interventions

Ginkgo Biloba Extract DRUG

Ginkgo Biloba Extract group

Placebo OTHER

Placebo group

Eligibility Criteria

• Age: 20 Years - 35 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Pregnant women in their third trimester (28-30 weeks of gestation).
• Pregnant women whose pregnancy was complicated with intra uterine growth restriction (IUGR).
• Normal Doppler indices in uterine, umbilical and middle cerebral arteries at time of recruitment.

You may not qualify if:

• Multiple pregnancies,
• Hypertension,
• Fetal congenital anomalies,
• Previous history of congenital anomalies or chromosomal abnormalities.
• Diabetes Mellitus
• Premature pre-labor rupture of membranes
• Antepartum hemorrhage

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Fetal Growth Retardation

Interventions

Ginkgo biloba extract

Condition Hierarchy (Ancestors)

Fetal Diseases; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Growth Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: April 21, 2015
• First Posted: April 24, 2015
• Study Start: May 1, 2014
• Primary Completion: October 1, 2015
• Study Completion: December 1, 2015
• Last Updated: March 22, 2016

Record last verified: 2016-03

Data Sharing

• IPD Sharing: Will share